Nipah Virus (NiV): Molecular Structure, Pathogenesis, and Research Reagents

1. Overview of Nipah Virus: Origins, Evolution, and Global Epidemiological Risks

Nipah virus (NiV), since its outbreak in Malaysia in 1998, has been recognized as a zoonotic virus with high mortality and significant cross-species transmission capabilities. This single-stranded negative-sense RNA virus is primarily carried by fruit bats (especially those of the genus PteropusPteropus) as natural hosts, can be transmitted to humans via intermediate hosts (such as pigs) or through direct exposure, and have formed stable genetic differentiation across different geographical regions. Phylogenetic studies indicate that NiV is primarily divided into the Bangladesh lineage (NiV-B) and the Malaysia lineage (NiV-M), reflecting the long-term evolutionary process of the virus within regional bat populations ^[1].

During cross-species transmission, the molecular adaptation of viruses to human receptors is a key factor determining their spillover risk. Research has found that the NiV G protein experiences significant selective pressure in its receptor-binding region, where variations at site 498 can modulate its affinity for the human ephrin-B2 receptor, thereby facilitating host jumping of the virus ^[1]. Additionally, positive selection signatures at site 1645 in the linker domain of the L protein suggest that viral replication and capping processes are also involved in host adaptation regulation.

The risk of Nipah virus (NiV) outbreaks closely aligns with the ecological distribution of its natural hosts. Ecological niche modeling indicates that approximately 19% (about 2.96 million km²) of South and Southeast Asia falls within high-risk zones ^[2]. Long-term serological surveillance reveals that NiV circulates persistently in wild fruit bat populations, with individual antibody levels showing dynamic fluctuations. Periodic viral recrudescence in bats is considered a key mechanism for sustaining transmission within populations and triggering sporadic human infections. While maternal antibodies can provide short-term protection, they are insufficient to prevent the long-term persistence of the virus ^[3].

In human populations, NiV infection typically exhibits an extremely high case fatality rate. For instance, during the 2018 outbreak in Kerala, India, the case fatality rate reached as high as 1%, highlighting the severe public health threat posed by the virus ^[4]. In vitro studies further indicate that NiV replicates significantly more efficiently in human respiratory epithelial cells than in porcine cells, a difference closely associated with the expression levels of the ephrin-B2 receptor ^[5]. In contrast, Cedar virus, another member of the Henipavirus genus, also utilizes ephrin-B2 for cellular entry but demonstrates markedly reduced pathogenicity in animal models due to the absence of key immune evasion factors ^[6]. This comparison provides important insights into the molecular basis of NiV's high pathogenicity and lays the groundwork for subsequent structural and intervention studies.

2. Fundamentals of Molecular Structure: Receptor Recognition and Membrane Fusion Trigger

2.1 Synergistic Mechanism of Surface Glycoproteins G and F

The initial step of Nipah virus infection of host cells relies on the highly coordinated action of two key glycoproteins on its envelope surface—the receptor-binding protein G and the fusion protein F. Unlike most paramyxoviruses, the NiV-G protein lacks hemagglutinin or neuraminidase activity. Instead, it recognizes the ephrin-B2 or ephrin-B3 receptors on the host cell surface through highly specific protein-protein interactions.

Structural biology studies have shown that the receptor-binding domain of the NiV-G protein exhibits a typical Six-leaf β-propeller structure In the complex, the loop structure of ephrin-B2/B3 inserts into the central groove of the G protein, forming an extensive interaction interface, where the Trp122 residue of ephrin-B2 plays a critical "latch"-like role, significantly enhancing binding affinity ^[7,8]. Deep mutational scanning results further reveal that alterations in G protein interface residues (such as Y228H) can significantly affect viral entry efficiency by modulating the stability and flexibility of the complex ^[9,10].

Receptor binding is not the endpoint but rather a molecular switch that triggers membrane fusion. Upon ephrin binding, the conformation of the G protein head undergoes rearrangement, and this signal is transmitted along the stalk, inducing an irreversible conformational change in the F protein, which is in a pre-fusion state ^[8]. The NiV-F protein in its pre-fusion state adopts a unique "Hexamer-of-trimers" Form assembly," this advanced structure is believed to help stabilize the higher-energy pre-fusion conformation and, upon triggering, cooperatively lower the energy barrier for fusion pore formation ^[11].

Research Tools:

Recombinant Nipah virus Glycoprotein G (G)-VLPs; CSB-MP862323NDT

Recombinant Nipah virus Glycoprotein G (G); CSB-CF862323NDT

Recombinant Nipah virus Fusion glycoprotein F0 (F), partial; CSB-MP884868NDT

Recombinant Human Ephrin type-B receptor 2 (EPHB2), partial; CSB-MP007730HU

Recombinant Human Ephrin type-B receptor 3 (EPHB3), partial; CSB-MP007731HU

2.2 Conformational Regulation of F Protein and Its Dependence on Membrane Environment

The cytoplasmic tail of the F protein plays an "inside-out" signaling role in fusion regulation. The KKR motif in its juxtamembrane region has been confirmed as a key regulatory element for fusion efficiency: mutations at different residues exert opposite effects on fusion activity and influence the formation rate of the six-helix bundle (6HB) by modulating the stability of the extracellular domain ^[13]. Additionally, the K2 residue is critical for the entry of the F protein into lipid raft regions, revealing an intrinsic link between spatial localization and functional activation.

N-glycosylation also plays a crucial role in maintaining protein function and facilitating immune evasion. The polysaccharide modification sites on the NiV-G protein can spatially shield the virus, limiting the recognition by neutralizing antibodies ^[15]. Meanwhile, host factors such as Galectin-1 can bind to the glycan chains of the F protein, inhibiting its conformational changes and thereby blocking membrane fusion as part of the host defense mechanism ^[16].

Research Tools:

Recombinant Human Galectin-1 (LGALS1); CSB-EP012882HU

3. Viral Replication Machinery: Replicase Complex and Nucleocapsid

The genome replication and transcription of Nipah virus are driven by a highly complex replicase system, with its core being the L-P complex composed of the large protein L and the phosphoprotein P. Cryo-electron microscopy studies reveal that the L protein integrates multiple functional modules, including RNA-dependent RNA polymerase (RdRp), PRNTase, and methyltransferase, while the P protein maintains overall structural stability in the form of a tetrameric helical bundle ^[17-19].

The NiV-L protein contains a long insertion structure that is relatively uncommon in other non-segmented negative-strand RNA viruses, which plays a critical role in regulating the balance between replication and transcription ^[19]. The XD linker of the P protein is uniquely anchored to the nucleotide entry channel region, and this conformational arrangement is believed to finely regulate substrate entry and the initiation of RNA synthesis ^[17].

At the nucleocapsid level, the genomic RNA is encapsulated by the N protein to form an α-helical structure. The N-P interaction is highly dependent on intrinsically disordered regions (IDRs), whose high flexibility facilitates efficient viral replication within the complex intracellular environment ^[23]. The stochastic assembly model proposed by super-resolution microscopy studies further indicates that viral replication and assembly are not entirely linear processes but exhibit a certain degree of randomness ^[24].

Research Tools:

Recombinant RNA-directed RNA polymerase L (L), partial; CSB-MP860779NDT

Recombinant Phosphoprotein (P/V/C), partial; CSB-MP878021NDT

4. Host-Pathogen Interaction and Immune Evasion Mechanisms

The high lethality of NiV largely stems from its highly sophisticated innate immune evasion strategy, in which the W protein encoded by the P gene plays a central role. By binding with high affinity to Importin-α3, the W protein competitively blocks the nuclear transport of key transcription factors such as STAT1, thereby suppressing the interferon signaling pathway ^[25].

Structural studies reveal that the C-terminal domain of the W protein can form dimers via disulfide bonds and induce a conformational transition from disorder to order in its N-terminal disordered region, even leading to the formation of amyloid-like structures ^[26]. This characteristic is believed to be potentially associated with the virus's long-term persistence within host cells and an increase in pathogenicity.

At the level of natural hosts, this immune evasion strategy translates into the virus's ability to establish latency and reactivation within bats, allowing for periodic viral shedding even in the presence of serum antibodies ^[3]. Furthermore, differences in ephrin-B2 expression levels across various hosts further shape infection efficiency and tissue tropism ^[5].

Research Tools:

Recombinant Protein W (P/V/C); CSB-MP313495NDT

Recombinant Human Importin subunit alpha-3 (KPNA3); CSB-MP012485HU

Recombinant Human Signal transducer and activator of transcription 1-alpha/beta (STAT1); CSB-EP022810HU

5. Preclinical Research Models and Evaluation Systems

Since NiV must be handled under BSL-4 conditions, developing safe and alternative evaluation models is crucial. The ferret model is widely used for validating therapeutic antibodies and vaccines due to its high similarity to human respiratory and neurological pathologies ^[27]. The human lung xenotransplantation mouse model demonstrates unique advantages in elucidating human-specific lung injury mechanisms ^[28].

In low biosafety level systems, the NiV-F/G pseudovirus system based on the HIV backbone can assess neutralizing antibody titers under BSL-2 conditions ^[29]. The chimeric virus platform based on Cedar virus achieves a good balance between biological relevance and safety ^[30]. Virus-like particles (VLPs) combine the value of immunogen presentation with the potential for mechanistic studies ^[31].

6. Therapeutic Intervention: Vaccine Strategies and Neutralizing Antibodies

Structure biology-driven antigen design has become a core direction in NiV vaccine development. The stabilized prefusion F protein (pre-F), which retains key neutralizing epitopes, has been demonstrated to possess significantly superior immunogenicity compared to the postfusion conformation ^[32]. Combining with G proteins or forming chimeric antigens can further expand the antibody repertoire ^[32,33].

In the field of therapeutic antibodies, hu1F5, which targets the pre-fusion conformation of the F protein, demonstrates significantly superior post-exposure protective efficacy compared to m102.4 in non-human primate models ^[34]. The membrane-distal domain (DIII) of the F protein is identified as a critical vulnerability site, serving as an important target for broad-spectrum intervention due to its strong functional constraints and low risk of escape mutations ^[35].

7. Recommend products

Recombinant Protein:

● Nipah virusProtein

Code	Product Name	Source
CSB-MP862323NDT	Recombinant Nipah virus Glycoprotein G (G)-VLPs	Mammalian cell
CSB-CF862323NDT	Recombinant Nipah virus Glycoprotein G (G)	in vitro E.coli expression system
CSB-MP884868NDT	Recombinant Nipah virus Fusion glycoprotein F0 (F), partial	Mammalian cell
CSB-MP860779NDT	Recombinant RNA-directed RNA polymerase L (L), partial	Mammalian cell
CSB-MP878021NDT	Recombinant Phosphoprotein (P/V/C), partial	Mammalian cell
CSB-MP313495NDT	Recombinant Protein W (P/V/C)	Mammalian cell

● Receptor proteins or related research proteins

Code	Product Name	Source
CSB-MP007730HU	Recombinant Human Ephrin type-B receptor 2 (EPHB2), partial	Mammalian cell
CSB-MP007731HU	Recombinant Human Ephrin type-B receptor 3 (EPHB3), partial	Mammalian cell
CSB-EP012882HU	Recombinant Human Galectin-1 (LGALS1)	E.coli
CSB-MP012485HU	Recombinant Human Importin subunit alpha-3 (KPNA3)	Mammalian cell
CSB-EP022810HU	Recombinant Human Signal transducer and activator of transcription 1-alpha/beta (STAT1)	E.coli

If other Nipah virus-related products or kits are needed, please contact us.

References

[1] Kemang Li, Shiyu Yan, Ningning Wang, Wanting He, Haifei Guan, Chengxi He, Zhixue Wang, Meng Lu, Wei He, Rui Ye, Michael Veit, Shuo Su.(2019). Emergence and adaptive evolution of Nipah virus.

[2] Mark A. Deka, Niaz Morshed.(2018). Mapping Disease Transmission Risk of Nipah Virus in South and Southeast Asia.

[3] A. R. Sohayati, Latiffah Hassan, Sharifah Syed Hassan, Karen Lazarus, C M Zaini, Jonathan H. Epstein, Norris Naim, Hume Field, Siti Suri Arshad, Jazli Aziz, Peter Daszak, EcoHealth Alliance.(2011). Evidence for Nipah virus recrudescence and serological patterns of captivePteropus vampyrus.

[4] Rima R. Sahay, Pragya D. Yadav, Nivedita Gupta, Anita M. Shete, Chandni Radhakrishnan, Ganesh Mohan, Nikhilesh Menon, Tarun Bhatnagar, Krishnasastry Suma, Abhijeet Kadam, Padinjaremattathil Thankappan Ullas, Brijesh Kumar, AP Sugunan, V. K. Sreekala, Rajan Khobragade, Raman Gangakhedkar, Devendra T. Mourya.(2020). Experiential learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public health emergencies in India.

[5] Lucie Sauerhering, Martin Zickler, Mareike Elvert, Laura Behner, Tatyana Matrosovich, Stephanie Erbar, Mikhail Matrosovich, Andrea Maisner.(2016). Species-specific and individual differences in Nipah virus replication in porcine and human airway epithelial cells.

[6] Glenn A. Marsh, Carol de Jong, Jennifer Barr, Mary Tachedjian, Craig Smith, Deborah Middleton, Meng Yu, Shawn Todd, Adam J. Foord, Volker Häring, Jean Payne, Rachel Robinson, Ivano Broz, Gary Crameri, Hume Field, Lin‐Fa Wang.(2012). Cedar Virus: A Novel Henipavirus Isolated from Australian Bats.

[7] Kai Xu, Kanagalaghatta R. Rajashankar, Yee‐Peng Chan, Juha P. Himanen, Christopher C. Broder, Dimitar B. Nikolov.(2008). Host cell recognition by the henipaviruses: Crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3.

[8] Kai Xu, Yee‐Peng Chan, Kanagalaghatta R. Rajashankar, Dimple Khetawat, Lianying Yan, Momchil V. Kolev, Christopher C. Broder, Dimitar B. Nikolov.(2012). New Insights into the Hendra Virus Attachment and Entry Process from Structures of the Virus G Glycoprotein and Its Complex with Ephrin-B2.

[9] Brendan B. Larsen, Teagan E. McMahon, Jack T Brown, Zhaoqian Wang, Caelan E. Radford, James E. Crowe, David Veesler, Jesse D. Bloom.(2025). Functional and antigenic landscape of the Nipah virus receptor-binding protein.

[10] Emre Aktaş, İrem Saygılı, E. Kahveci, Zeynep Tekbıyık, Nehir Özdemir Özgentürk.(2023). Bioinformatic investigation of Nipah virus surface protein mutations: Molecular docking with Ephrin B2 receptor, molecular dynamics simulation, and structural impact analysis.

[11] Kai Xu, Yee‐Peng Chan, Birgit Bradel-Tretheway, Zeynep Akyol-Ataman, Yongqun Zhu, Somnath Dutta, Lianying Yan, YanRu Feng, Lin‐Fa Wang, Georgios Skiniotis, Benhur Lee, Z. Hong Zhou, Christopher C. Broder, Hector C. Aguilar, Dimitar B. Nikolov.(2015). Crystal Structure of the Pre-fusion Nipah Virus Fusion Glycoprotein Reveals a Novel Hexamer-of-Trimers Assembly.

[12] Sofia Cheliout Da Silva, Lianying Yan, Ha V. Dang, Kai Xu, Jonathan H. Epstein, David Veesler, Christopher C. Broder.(2021). Functional Analysis of the Fusion and Attachment Glycoproteins of Mojiang Henipavirus.

[13] Hector C. Aguilar, Kenneth A. Matreyek, Daniel Choi, Claire Marie Filone, Sophia Young, Benhur Lee.(2007). Polybasic KKR Motif in the Cytoplasmic Tail of Nipah Virus Fusion Protein Modulates Membrane Fusion by Inside-Out Signaling.

[14] Michael Weis, Laura Behner, Markus Hoffmann, Nadine Krüger, Georg Herrler, Christian Drosten, Jan Felix Drexler, Erik Dietzel, Andrea Maisner.(2013). Characterization of African bat henipavirus GH-M74a glycoproteins.

[15] Birgit Bradel-Tretheway, Qian Liu, Jacquelyn A. Stone, Samantha McInally, Hector C. Aguilar.(2015). Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus.

[16] Omai B. Garner, Hector C. Aguilar, Jennifer A. Fulcher, Ernest L. Levroney, Rebecca A. Harrison, Lacey Wright, Lindsey R. Robinson, Vanessa Aspericueta, Maria Panico, Stuart M. Haslam, Howard R. Morris, Anne Dell, Benhur Lee, Linda G. Baum.(2010). Endothelial Galectin-1 Binds to Specific Glycans on Nipah Virus Fusion Protein and Inhibits Maturation, Mobility, and Function to Block Syncytia Formation.

[17] Xue Lu, Tiancai Chang, Jiawei Gui, Zimu Li, Heyu Zhao, B. S. Zou, Junnan Lu, Mei Li, Xin Wen, Shenghua Gao, Shujing Xu, Lijun Rong, Liqiang Feng, Peng Gong, Jun He, Xinwen Chen, Xiaoli Xiong.(2025). Cryo-EM structures of Nipah virus polymerase complex reveal highly varied interactions between L and P proteins among paramyxoviruses.

[18] Jonathan M. Grimes, Franziska Günl, Loïc Carrique, J.R. Keown, Ervin Fodor, Ervin Fodor.(2024). Structure of the Nipah virus polymerase complex.

[19] Side Hu, Heesu Kim, Pan Yang, Zishuo Yu, Barbara Ludeke, Shawna Mobilia, Junhua Pan, Margaret M. Stratton, Yuemin Bian, Rachel Fearns, Jonathan Abraham.(2024). Structural and functional analysis of the Nipah virus polymerase complex.

[20] F. Sala, Katja Ditter, Olexandr Dybkov, Henning Urlaub, Hauke S. Hillen.(2025). Structural basis of Nipah virus RNA synthesis.

[21] Paul C. Jordan, Cheng Liu, Pauline Raynaud, Michael K. Lo, Christina F. Spiropoulou, Julian Symons, Leo Beigelman, Jérôme Deval.(2018). Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase.

[22] Jin Xie, Mohamed Ouizougun-Oubari, Li Wang, Guanglei Zhai, Daitze Wu, Zhaohu Lin, Manfu Wang, Barbara Ludeke, Xiaodong Yan, Tobias Nilsson, Lu Gao, Xinyi Huang, Rachel Fearns, Shuai Chen.(2024). Structural basis for dimerization of a paramyxovirus polymerase complex.

[23] Johnny Habchi, Laurent Mamelli, Hervé Darbon, Sonia Longhi.(2010). Structural Disorder within Henipavirus Nucleoprotein and Phosphoprotein: From Predictions to Experimental Assessment.

[24] Qian Liu, Lei Chen, Hector C. Aguilar, Keng C. Chou.(2018). A stochastic assembly model for Nipah virus revealed by super-resolution microscopy.

[25] K.M. Smith, S. Tsimbalyuk, Megan R. Edwards, E.M. Cross, Jyoti Batra, Tatiana P. Soares da Costa, David Aragão, Christopher F. Basler, Jade K. Forwood.(2018). Structural basis for importin alpha 3 specificity of W proteins in Hendra and Nipah viruses.

[26] Giulia Pesce, Frank Gondelaud, Denis Ptchelkine, Christophe Bignon, Patrick Fourquet, Sonia Longhi.(2024). DissectingHenipavirusW proteins conformational and fibrillation properties: contribution of their N‐ and C‐terminal constituent domains.

[27] Katharine N. Bossart, Zhongyu Zhu, Deborah Middleton, Jessica Klippel, Gary Crameri, John Bingham, Jennifer A. McEachern, Diane Green, Timothy J. Hancock, Yee‐Peng Chan, Andrew C. Hickey, Dimiter S. Dimitrov, Lin‐Fa Wang, Christopher C. Broder.(2009). A Neutralizing Human Monoclonal Antibody Protects against Lethal Disease in a New Ferret Model of Acute Nipah Virus Infection.

[28] Gustavo Valbuena, Hailey Halliday, Viktoriya Borisevich, Yenny Góez, Barry Rockx.(2014). A Human Lung Xenograft Mouse Model of Nipah Virus Infection.

[29] Jianhui Nie, Lin Liu, Qing Wang, Ruifeng Chen, Tingting Ning, Qiang Liu, Weijin Huang, Youchun Wang.(2019). Nipah pseudovirus system enables evaluation of vaccinesin vitroandin vivousing non-BSL-4 facilities.

[30] Moushimi Amaya, Randy Yin, Lianying Yan, Viktoriya Borisevich, Bishwo N. Adhikari, Andrew J. Bennett, Francisco Malagón, Regina Z. Cer, Kimberly A. Bishop‐Lilly, Antony S. Dimitrov, Robert W. Cross, Thomas W. Geisbert, Christopher C. Broder.(2023). A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses.

[31] Lori W. McGinnes, Homer Pantua, Jason P. Laliberte, Kathryn A. Gravel, Surbhi Jain, Trudy G. Morrison.(2010). Assembly and Biological and Immunological Properties of Newcastle Disease Virus-Like Particles.

[32] Rebecca J. Loomis, Guillaume B. E. Stewart-Jones, Yaroslav Tsybovsky, Ria T. Caringal, Kaitlyn M. Morabito, Jason S. McLellan, Amy L. Chamberlain, Sean Nugent, Geoffrey B. Hutchinson, Lisa A. Kueltzo, John R. Mascola, Barney S. Graham.(2020). Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development.

[33] Seo Young Moon, Rochelle A. Flores, Min Su Yim, Heeji Lim, Seung-Yeon Kim, Seung Yun Lee, Yoo-kyoung Lee, Jae‐Ouk Kim, Hyejin Park, Seong Eun Bae, In-Ohk Ouh, Woo Hyun Kim.(2024). Immunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus.

[34] Larry Zeitlin, Robert W. Cross, Courtney Woolsey, Brandyn R. West, Viktoriya Borisevich, Krystle N. Agans, Abhishek N. Prasad, Daniel J. Deer, Lauren Stuart, Maria McCavitt-Malvido, Do H. Kim, James Pettitt, James E. Crowe, Kevin J. Whaley, David Veesler, Antony S. Dimitrov, Dafna M. Abelson, Thomas W. Geisbert, Christopher C. Broder.(2024). Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates.

[35] Victoria A. Avanzato, Kasopefoluwa Y. Oguntuyo, Marina Escalera‐Zamudio, Bernardo Gutiérrez, Michael Golden, Sergei L. Kosakovsky Pond, Rhys Pryce, Thomas S. Walter, Jeffrey Seow, Katie J. Doores, Oliver G. Pybus, Vincent J. Munster, Benhur Lee, Thomas A. Bowden.(2019). A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex.

Nipah Virus Research Hub: From Molecular Mechanisms to Therapeutic Development

1. Overview of Nipah Virus: Origins, Evolution, and Global Epidemiological Risks

2. Fundamentals of Molecular Structure: Receptor Recognition and Membrane Fusion Trigger

2.1 Synergistic Mechanism of Surface Glycoproteins G and F

Research Tools:

2.2 Conformational Regulation of F Protein and Its Dependence on Membrane Environment

Research Tools:

3. Viral Replication Machinery: Replicase Complex and Nucleocapsid

Research Tools:

4. Host-Pathogen Interaction and Immune Evasion Mechanisms

Research Tools:

5. Preclinical Research Models and Evaluation Systems

6. Therapeutic Intervention: Vaccine Strategies and Neutralizing Antibodies

7. Recommend products

Recombinant Protein: